Anterix, Inc. (ATEX)

NASDAQCommunication ServicesTelecommunications ServicesSnapshot 2026-10-23

$74.90+2.38%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Anterix, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	2.13M
EPS	—	-0.413
Annual ending 2027-03-31
Revenue	—	21.64M
EPS	—	-0.873
Annual ending 2028-03-31
Revenue	—	19.59M
EPS	—	-1.53

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Cash from operations improves to positive $15.5 million in Q4 2026	Cash from operations turned positive $15.5M, showing strong financial progress.	Improving	cash from operations falls below $5 million in Q4 2026	Cash from operations: $2.045M FY2027-Q1; GAAP. Published target: >= $15.5 million. The stored target says 2026-Q4; this source reports FY2027-Q1. Fiscal/calendar alignment needs review. Source published Aug 11, 20262,045,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2027-Q1. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Operating income improved from -$9.061 million in 2026-Q3 to -$0.246 million in 2027-Q1, and cash from operations improved from -$8.272 million to $2.045 million over the same period. The trajectory shows delivering progress on improving operating income and cash flow. Delivery assessment Oct 24, 2026
Achieve over $80 million in contracted proceeds in Q4 2026	Anterix aims to secure over $80M in contracted proceeds in Q4 2026.	Improving	contracted proceeds fall below $70 million in Q4 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating income improves to positive $19.8 million in Q4 2026	Operating income improved from negative $9.1M to positive $19.8M in Q4 2026.	Improving	operating income falls below $10 million in Q4 2026	Operating income: $-246,000 FY2027-Q1; GAAP. Published target: >= $19.8 million. The stored target says 2026-Q4; this source reports FY2027-Q1. Fiscal/calendar alignment needs review. Source published Aug 11, 2026-246,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: e18896df-16d6-486a-8391-74bc14725e86. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Operating income improved from -$9.061 million in 2026-Q3 to -$0.246 million in 2027-Q1, and cash from operations improved from -$8.272 million to $2.045 million over the same period. The trajectory shows delivering progress on improving operating income and cash flow. Delivery assessment Oct 24, 2026
Revenue reaches $25.3 million in fiscal year 2027	A primary condition in Anterix, Inc.'s published investment case. The stated target is >= $25.3 million.	Intact	revenue falls below $20 million in fiscal 2027	Revenue: $1.958M FY2027-Q1; GAAP. Published target: >= $25.3 million. Target period is not explicitly aligned with this observation. Source published Aug 11, 20261,958,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: e18896df-16d6-486a-8391-74bc14725e86. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management set revenue guidance at $25.3 million for fiscal year 2027. Actual quarterly revenues were $1.958 million in 2027-Q1, consistent with the annual guidance trajectory. The priority is newly emphasized and progress is early. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-03-31 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 1
2026-07-25	Unavailable	Unavailable	2 / 1
2026-07-26	Unavailable	Unavailable	1 / 1
2026-07-27	Unavailable	Unavailable	1 / 1
2026-07-28	Unavailable	Unavailable	2 / 1
2026-07-29	Unavailable	Unavailable	2 / 1
2026-07-30	Unavailable	Unavailable	2 / 1
2026-07-31	Unavailable	Unavailable	2 / 1
2026-08-01	Unavailable	Unavailable	2 / 1
2026-08-02	Unavailable	Unavailable	2 / 1
2026-08-03	Unavailable	Unavailable	2 / 1
2026-08-04	Unavailable	Unavailable	2 / 1
2026-08-05	Unavailable	Unavailable	1 / 1
2026-08-06	Unavailable	Unavailable	2 / 1
2026-08-07	Unavailable	Unavailable	1 / 1
2026-08-08	Unavailable	Unavailable	2 / 1
2026-08-09	Unavailable	Unavailable	2 / 1
2026-08-10	Unavailable	Unavailable	2 / 1
2026-08-11	Unavailable	Unavailable	2 / 1
2026-08-12	Unavailable	Unavailable	2 / 1
2026-08-13	Unavailable	Unavailable	2 / 1
2026-08-14	Unavailable	Unavailable	1 / 1
2026-08-15	Unavailable	Unavailable	1 / 1
2026-08-16	Unavailable	Unavailable	2 / 2
2026-08-17	Unavailable	Unavailable	2 / 2
2026-08-18	Unavailable	Unavailable	2 / 2
2026-08-19	Unavailable	Unavailable	2 / 1
2026-08-20	Unavailable	Unavailable	2 / 1
2026-08-21	Unavailable	Unavailable	2 / 2
2026-08-22	Unavailable	Unavailable	2 / 2
2026-08-23	Unavailable	Unavailable	2 / 2
2026-08-24	Unavailable	Unavailable	2 / 2
2026-08-25	Unavailable	Unavailable	2 / 2
2026-08-26	Unavailable	Unavailable	2 / 2
2026-08-27	Unavailable	Unavailable	2 / 2
2026-08-28	Unavailable	Unavailable	2 / 2
2026-08-29	Unavailable	Unavailable	2 / 2
2026-08-30	Unavailable	Unavailable	2 / 2
2026-08-31	Unavailable	Unavailable	2 / 2
2026-09-01	Unavailable	Unavailable	2 / 2
2026-09-02	Unavailable	Unavailable	2 / 2
2026-09-03	Unavailable	Unavailable	2 / 2
2026-09-04	Unavailable	Unavailable	2 / 2
2026-09-05	Unavailable	Unavailable	2 / 2
2026-09-06	Unavailable	Unavailable	2 / 2
2026-09-07	Unavailable	Unavailable	2 / 2
2026-09-08	Unavailable	Unavailable	2 / 2
2026-09-09	Unavailable	Unavailable	2 / 2
2026-09-10	Unavailable	Unavailable	2 / 2
2026-09-11	Unavailable	Unavailable	2 / 2
2026-09-12	Unavailable	Unavailable	2 / 2
2026-09-13	Unavailable	Unavailable	2 / 2
2026-09-14	Unavailable	Unavailable	2 / 2
2026-09-15	Unavailable	Unavailable	2 / 2
2026-09-16	Unavailable	Unavailable	2 / 2
2026-09-17	Unavailable	Unavailable	2 / 2
2026-09-18	Unavailable	Unavailable	2 / 2
2026-09-19	Unavailable	Unavailable	2 / 2
2026-09-20	Unavailable	Unavailable	2 / 2
2026-09-21	Unavailable	Unavailable	2 / 2
2026-09-22	Unavailable	Unavailable	2 / 2
2026-09-23	Unavailable	Unavailable	2 / 2
2026-09-24	Unavailable	Unavailable	2 / 2
2026-09-25	Unavailable	Unavailable	2 / 2
2026-09-26	Unavailable	Unavailable	2 / 2
2026-09-27	Unavailable	Unavailable	2 / 2
2026-09-28	Unavailable	Unavailable	2 / 2
2026-09-29	Unavailable	Unavailable	2 / 2
2026-09-30	Unavailable	Unavailable	2 / 2
2026-10-01	Unavailable	Unavailable	2 / 2
2026-10-02	Unavailable	Unavailable	2 / 2
2026-10-03	Unavailable	Unavailable	2 / 2
2026-10-04	Unavailable	Unavailable	2 / 2
2026-10-05	Unavailable	Unavailable	2 / 2
2026-10-06	Unavailable	Unavailable	2 / 2
2026-10-07	Unavailable	Unavailable	2 / 2
2026-10-08	Unavailable	Unavailable	2 / 2
2026-10-09	Unavailable	Unavailable	2 / 2
2026-10-10	Unavailable	Unavailable	2 / 2
2026-10-11	Unavailable	Unavailable	2 / 2
2026-10-12	Unavailable	Unavailable	2 / 2
2026-10-13	Unavailable	Unavailable	2 / 2
2026-10-14	Unavailable	Unavailable	2 / 2
2026-10-15	Unavailable	Unavailable	2 / 2
2026-10-16	Unavailable	Unavailable	2 / 2
2026-10-17	Unavailable	Unavailable	2 / 2
2026-10-18	Unavailable	Unavailable	2 / 2
2026-10-19	Unavailable	Unavailable	2 / 2
2026-10-20	Unavailable	Unavailable	2 / 2
2026-10-21	Unavailable	Unavailable	2 / 2
2026-10-22	Unavailable	Unavailable	2 / 2
2026-10-23	Unavailable	Unavailable	2 / 2
2026-10-24	Unavailable	Unavailable	2 / 2

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	3	0
2026-06-01	3	1
2026-07-01	2	1
2026-08-01	2	1
2026-09-01	2	1
2026-10-01	2	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Cash from operations improves to positive $15.5 million in Q4 2026Cash from operations: $2.045M
Achieve over $80 million in contracted proceeds in Q4 2026Direct metric needs a verified mapping
Operating income improves to positive $19.8 million in Q4 2026Operating income: $-246,000
Revenue reaches $25.3 million in fiscal year 2027Revenue: $1.958M

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-32.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Anterix, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a higher-risk growth and execution story, not a proven durable compounder. The long-term thesis is intact, with recent results holding in the top half of its industry, but confidence has eased from high to medium.

What's priced into Anterix, Inc.

ATEX is expensive versus peers, and the evidence flags the expectations gap as unjustified, with a possible re-rating driving the valuation. The valuation model has low confidence, so the market’s assumptions are hard to judge precisely.

What the fundamentals likely do

Near term, management has shown progress: operating income and cash from operations improved between 2026-Q3 and 2027-Q1, and recent earnings beats offer support. However, fiscal 2027 revenue guidance is still early to assess, contracted proceeds remain a key collection goal, and a guidance cut would be a meaningful setback.

What Anterix, Inc. hinges on

The multi-year view hinges on management collecting the targeted contracted proceeds, progressing toward fiscal 2027 revenue guidance, and sustaining improvements in operating income and cash flow. Near-term sector conditions could help if rates ease or major communication services companies keep reporting strong results, while a guidance cut or renewed execution weakness would weigh on the thesis.